In this real-world exploratory longitudinal study, we evaluated the dynamics of serum calprotectin, CRP, and DAS28 over a six-month period in RA patients treated with adalimumab, upadacitinib, or tocilizumab. This evidence concerns the gene CRP and rheumatoid arthritis.